Halozyme Therapeutics layoffs, on the record
Every job cut, severance charge and restructuring Halozyme Therapeutics reported in its annual reports, 2023 to 2025, quoted from the filings.
Job cuts, severance and restructuring
Our summaryThe filing says that if additional capital is not available on favorable terms, the company may significantly reduce operating expenses through restructuring of its operations.
Word for word“If additional capital is not available on favorable terms when needed, we will be required to raise capital on adverse terms or significantly reduce operating expenses through the restructuring of our operations or deferral of strategic business initiatives.” 10-K for 2023
Halozyme Therapeutics filed 2 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Halozyme Therapeutics’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-17. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.